New drug hopes to curb rare genetic obesity
NCT ID NCT07220772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called mibavademab in people with a rare form of obesity caused by a faulty leptin gene. The drug aims to help control hunger and body weight. Only 4 participants will be enrolled to see how well it works and if it is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mibavademab (a leptin receptor agonist)
- What this could lead to
- If it works, this could provide a treatment option for people with a rare form of obesity caused by a faulty leptin gene.
- What could go wrong
- This is a very small early-phase trial with only 4 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOGENIC OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ULM University Medical Centre
RECRUITINGUlm, 89075, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.